宏强控股(08262.HK)与广西博繁订立合作框架协议
格隆汇 4 月 27日丨宏强控股(08262.HK)宣布,于2021年4月27日,公司及广西博繁科技发展有限公司("广西博繁")就中国广西南宁市的潜在项目签订了合作框架协议。广西博繁的主营业务为物联网産品生産及医疗软件开发和系统集成。
根据合作框架协议,公司有意与广西博繁合作的内容包括但不限于以下领域:博繁工业物联网産品生産及区块链物联网研发总部基地项目工程建设;及工业区块链、智慧云平台、大数据分析系统中心建设。
公司将与广西博繁就上述潜在项目的合作内容、合作方式等具体合作事项进行磋商。
董事会认为与广西博繁的合作能拓展公司在中国的工程建设业务及增加其它业务发展的可能性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.